{"groups":[{"description":"Participants received bortezomib 1.3 mg/m\\^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and placebo intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. At the completion of the 8-cycle treatment phase, participants entered the observation phase until disease progression.","id":"FG000","title":"BORT + P"},{"description":"Participants received bortezomib 1.3 mg/m\\^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and bevacizumab 15 mg/kg administered by intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. After completion of 8 cycles, participants could continue to receive bevacizumab as monotherapy until disease progression.","id":"FG001","title":"BORT + BV"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"20"}],"type":"Progression not resulting in death"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"5"}],"type":"Non-protocol-specified therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"3"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"53"},{"groupId":"FG001","numSubjects":"49"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"52"},{"groupId":"FG001","numSubjects":"48"}],"type":"Treated"},{"achievements":[{"comment":"2 patients received at least 1 bevacizumab dose \\& were analyzed as bevacizumab-treated patients","groupId":"FG000","numSubjects":"50"},{"groupId":"FG001","numSubjects":"50"}],"type":"Safety Population"},{"achievements":[{"comment":"Continuing on study as of the data cutoff date of 9 November 2009.","groupId":"FG000","numSubjects":"8"},{"comment":"Continuing on study as of the data cutoff date of 9 November 2009.","groupId":"FG001","numSubjects":"11"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"38"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Phase II, randomized, blinded, placebo-controlled, multicenter study designed to provide a preliminary assessment of the safety and efficacy of combining bevacizumab with bortezomib in patients with relapsed or refractory multiple myeloma starting 11 July 2007 and completing 9 November 2009."}